Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp185 | Benign Thyroid Disorders | ECE2019

Thyroid-related adverse events in patients treated with Nivolumab and Pembrolizumab

Sbardella Emilia , Tenuta Marta , Sirgiovanni Grazia , Pozza Carlotta , Gianfrilli Daniele , Mazzotta Paola , Pandozzi Carla , Cortesi Enrico , Lenzi Andrea , Gelibter Alain J , Isidori Andrea M

Introduction: Immune-Checkpoint Inhibitors (ICI) are frequently associated with thyroid-related adverse events (AE). Several studies analyzed thyroid disfunctions during ICI therapy, but many aspects remain to be characterized, especially for the most recent anti-PD-1 drugs. The aim of this study is to determine incidence and characteristics of PD-1 inhibitors associated thyroid dysfunction.Methods: We retrospectively analyzed data of patients with advan...